Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

GlobeNewswire

MOUNTAIN VIEW, Calif., Oct. 21, 2026 -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027.

  1. CryptoAlpha Modus Highlights Bitcoin Holdings with Value Exceeding $250 Million*, Potential $225 Million in Additional Cash Proceeds, ARIA Expansion Targeting Over 20,000 Retail Locations and Significant Federal Patent Litigation MilestonesAlpha Modus highlights $250M+ in Bitcoin, $225M in potential warrant proceeds, ARIA's 20,000+ retail pipeline and federal patent litigation progress.
  2. FinanceHIIHII Increases Quarterly Dividend to $1.41 per ShareCompanies: Huntington Ingalls IndustriesHII (NYSE: HII) announced today that its Board of Directors has declared a quarterly cash dividend of $1.41 per share, a $0.03 increase over the $1.38 per share dividend paid in each of the prior four quarters. The $1.41 per share dividend will be payable on Dec. 11, 2026, to shareholders of record as of the close of business on Nov. 27, 2026.
  3. Biotech & pharmaIMUNON Announces Strategic Sale of ThermoDox®Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial
  4. CryptoRunItUp Creators Earn More Than $63,000 as Trading Passes $2.9M Across Five ChainsRunItUp, a multichain token launchpad live on Robinhood Chain, BNB Chain, Ethereum, Base and Arc, has passed $2.9 million in trading volume across nearly 30,000 trades. According to platform data as of Oct. 19, 2026, 404 tokens have launched across the five mainnets, 115 creators earn trading fees, and creators have been paid more than $63,000 in total.
  5. Food & drinkRentomojo Announces New Furniture and Appliances for Rent for a 3BHK in Delhi in 2026: Three Bedrooms, a Six-Seater Dining Set and a Living Room for About ₹6,061 a Month Against About ₹1.55 Lakh to BuyThree Furnished Bedrooms, a Three-Seater Sofa, Coffee Table and Six-Seater Dining Set Rent for About ₹6,061 a Month in Delhi, About ₹7,225 With a Fridge and Washing Machine and About ₹8,343 With a 43-Inch Smart TV; Families Can Add a 1.5-Ton AC at ₹1,997, Furnish in Stages and Move the Whole Setup Free Within Delhi
  6. Onicor Appoints Antifungal Pioneer Piet De Doncker, PhD, as CEO to Advance Personalized Treatment for Fungal Nail InfectionsDutch medtech Onicor names Piet De Doncker, PhD, CEO to lead its personalized nail orthosis for onychomycosis, a common and hard-to-treat nail infection.